Intensive chemotherapy versus autologous or allogeneic stemcell transplantation for the treatment of patients with poor risk MDS and secondary AML-A joint study of the Eortc, Ebmt, Hovon, Swiss, Scandinavian and Gimema leukemia groups: A biomed-2 EU-project.

deWitte, T., Ferrant, A., Suciu, S., Anak, O., Hagemeijer, A., Selleslag, D., Delforge, M., Belhabi, A., Schouten, H., Gratwohl, A., Aul, C., Aivado, M., Amadori, S., Muus, P., Tigaud, I., Jotterand-Bellomo, M., & Willemze, R. (1999). Intensive chemotherapy versus autologous or allogeneic stemcell transplantation for the treatment of patients with poor risk MDS and secondary AML-A joint study of the Eortc, Ebmt, Hovon, Swiss, Scandinavian and Gimema leukemia groups: A biomed-2 EU-project. Blood, 94(10), 382B-382B. (Original work published 1999)